{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-149364","form_type":"8-K","ticker":"PFE","cik":"0000078003","company_name":"PFIZER INC","filed_at":"2023-05-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.215828+00:00","generated_at":"2026-06-14T20:21:32.637519+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Pfizer completes $31B multi-tranche note offering to fund Seagen acquisition","bullets":["Issued $31B aggregate principal across 8 tranches: 2025-2063 maturities, rates 4.45%-5.34%.","Notes fully and unconditionally guaranteed by Pfizer on a senior unsecured basis.","Special mandatory redemption at 101% if Seagen merger not consummated by Sep 19, 2024 or abandoned.","Net proceeds to finance portion of Seagen deal consideration and related fees; proceeds of 2033/2053 notes for general corporate purposes if redemption triggered.","Issued by wholly-owned Singapore subsidiary Pfizer Investment Enterprises Pte. Ltd."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-149364","json":"https://secwatch.observer/filing/0001193125-23-149364.json","markdown":"https://secwatch.observer/filing/0001193125-23-149364.md","text":"https://secwatch.observer/filing/0001193125-23-149364.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/78003/000119312523149364/0001193125-23-149364-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/78003/000119312523149364/d414076d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T20:21:32.637519+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}